

RECEIVED
SECRETARY OF THE SENATE
PUBLIC RECORDS

03 AUG 13 PM 1:06:31

| | |
|---|--|
| Clerk of the House of Representatives Legislative Resource Center B-105 Cannon Building Washington, DC 20515 | Secretary of the Senate Office of Public Records 332 Hart Building Washington, DC 20510 |
|---|--|

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

| | |
|---|-----------------------------------|
| 1. Registrant Name Hoffmann-La Roche Inc. | |
| 2. Address <input type="checkbox"/> Check if different than previous 1300 I Street, NW Suite 520 West Washington, D.C. 20005-3314 | |
| 3. Principal Place of Business Nutley City: New Jersey State/zip for Correspondence: | Telephone: (202) 408-0090 |
| 4. Contact Name Candace Sams | 5. Senate ID # 18411-12 |
| 6. Client Name <input checked="" type="checkbox"/> Self Self | 7. House ID # 31167000 |
| Email: candace.sams@roche.com | |

8. Year 2003 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____ 11. No Lobbying Activities

| INCOME OR EXPENSES - Complete Either Line 12 OR Line 13 | |
|--|--|
| <p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p> | <p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>\$1,973,702</u> Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of option:</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions of lobbying</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of Internal Revenue Code</p> |

Signature *Michael Eging* Date 8/12/03

Printed Name and Title Michael Eging, Exec. Dir., Federal Gov't Affairs & Public Policy

00000263111

Registrant Name Hoffmann-La Roche Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

Taxation/Internal Revenue Code
HR 5029

17. House(s) of Congress and Federal agencies contacted Check if None

United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) | New |
|---------------|--|--------------------------|
| Michael Eging | Executive Director, Federal Government Affairs | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Roche Holding Ltd.—100% ownership in client F. Hoffmann-La Roche Ltd.—Interests similar to those of client

Signature  Date 8/12/03

Printed Name and Title Michael Eging, Exec. Dir., Federal Gov'n Affairs & Public Policy

101000263112

Registrant Name Hoffmann-La Roche Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

Intellectual Property/Patent related Issues
Hatch-Waxman Reform
S.812 - Greater Access to Affordable Pharmaceuticals Act of 2001

17. House(s) of Congress and Federal agencies contacted Check if None


United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|---------------|--|
| Michael Eging | Executive Director, Federal Government Affairs |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Roche Holding Ltd.—100% ownership in client F. Hoffmann-La Roche Ltd.—Interests similar to those of client

Signature  Date 8/12/03
Printed Name and Title Michael Eging, Exec. Dir., Federal Gov'n't Affairs & Public Policy

00000263113

Registrant Name Hoffmann-La Roche Inc. Client Name _____

Self _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

| |
|--|
| Health Issues |
| S.2729 - Amend Title XVIII of Social Security Act to provide for a Medicare voluntary prescription drug delivery program |
| S.2766 - Making appropriations for the Departments of Labor, HHS & Education |
| S.987 - To amend Title XIX of Social Security Act to permit States the option to provide Medicaid coverage for HIV |
| S.1976 - Provide for a comprehensive federal effort relating to treatments for and prevention of cancer |
| S.710 - To require coverage for colorectal cancer screenings |
| S.1931 - Amend Title XVIII of Social Security Act to improve patient access to, and utilization of, the colorectal cancer screening benefit under Medicare program |

17. House(s) of Congress and Federal agencies contacted Check if None

| |
|--|
| United States House of Representatives |
| United States Senate |

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Current Official Position (if applicable) | N |
|----------------------|--|-----|
| <u>Michael Eging</u> | Executive Director, Federal Government Affairs | [] |
| | | [] |
| | | [] |
| | | [] |
| | | [] |
| | | [] |
| | | [] |
| | | [] |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Roche Holding Ltd.--100% ownership in client F. Hoffmann-La Roche Ltd.--Interests similar to those of client

Signature  Date 8/12/03

Printed Name and Title Michael Eging, Exec. Dir., Federal Gov'n Affairs & Public Policy

Registrant Name Hoffmann-La Roche Inc Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

| |
|--|
| Health Issues |
| S.812 - Greater Access to Affordable Pharmaceuticals Act of 2001 |
| S.193 - Access to Cancer Therapies Act |
| HR 2887 - Best Pharmaceuticals for Children Act |
| S.838 - Best Pharmaceuticals for Children Act |
| S.1032 - International Infectious Diseases Control Act |
| HR 3252 - Fair Balance Prescription Drug Advertisement Act |
| S.847 - Early Treatment for HIV Act of 2003 |

17. House(s) of Congress and Federal agencies contacted Check if None

| |
|--|
| United States House of Representatives |
| United States Senate |

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) | Net |
|---------------|--|--------------------------|
| Michael Eging | Executive Director, Federal Government Affairs | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Roche Holding Ltd.--100% ownership in client F. Hoffmann-La Roche Ltd.--Interests similar to those of client

Signature: *Michael Eging* Date: 8/12/03
 Printed Name and Title: Michael Eging, Exec. Dir., Federal Gov'n Affairs & Public Policy

1000002101

Registrant Name Hoffmann-La Roche Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Health Issues
S. 1147 - Hepatitis C Epidemic Control and Prevention Act

17. House(s) of Congress and Federal agencies contacted Check if None

United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) | New |
|---------------|--|--------------------------|
| Michael Eging | Executive Director, Federal Government Affairs | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |
| | | <input type="checkbox"/> |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Roche Holding Ltd.—100% ownership in client F. Hoffmann-La Roche Ltd.—Interests similar to those of client

Signature *Michael Eging* Date 8/12/03
Printed Name and Title Michael Eging, Exec. Dir. Federal Gov't Affairs & Public Policy

0
0
0
0
0
0
0
0
0
0

Registrant Name Hoffmann-La Roche Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare/Medicaid
 HR 1641 - Medicaid Obesity Treatment Act
 S.2625 - Amend Title XVIII of Social Security Act to provide coverage of outpatient prescription drugs under the Medicare Program
 HR 4360 - Amend Title XVIII of Social Security Act to provide voluntary program for prescription drug coverage under Medicare
 HR 1839 - Immunosuppressive Drug Coverage Act
 S.880 - Immunosuppressive Drug Coverage Act

17. House(s) of Congress and Federal agencies contacted Check if None


United States House of Representatives
 United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) | Ne |
|---------------|--|-------------------------------------|
| Michael Eging | Executive Director, Federal Government Affairs | <input checked="" type="checkbox"/> |
| Nimish Shah | Manager, Public Policy | <input checked="" type="checkbox"/> |
| | | <input checked="" type="checkbox"/> |
| | | <input checked="" type="checkbox"/> |
| | | <input checked="" type="checkbox"/> |
| | | <input checked="" type="checkbox"/> |
| | | <input checked="" type="checkbox"/> |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Roche Holding Ltd.—100% ownership in client F. Hoffmann-La Roche Ltd.—Interests similar to those of client

Signature:  Date: 8/12/03
 Printed Name and Title: Michael Eging, Exec. Dir., Federal Gov't Affairs & Public Policy

0000263117

Registrant Name Hoffmann-La Roche Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Medicare/Medicaid
HR 3032 - Medicare Coverage of Immunosuppressives Drug Coverage
S.1204 - Comprehensive Immunosuppressive Drug Coverage Act
S.358 - Medicare Prescription Drug and Modernization Act

17. House(s) of Congress and Federal agencies contacted Check if None

United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) | N |
|---------------|--|---|
| Michael Eging | Executive Director, Federal Government Affairs | 1 |
| Nimish Shah | Manager, Public Policy | 1 |
| | | 1 |
| | | 1 |
| | | 1 |
| | | 1 |
| | | 1 |
| | | 1 |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Roche Holding Ltd.—100% ownership in client F. Hoffmann-La Roche Ltd.—interests similar to those of client

Signature *Michael Eging* Date 8/12/03
Printed Name and Title Michael Eging, Exec. Dir., Federal Gov't Affairs & Public Policy

00000263118

Registrant Name Hoffmann-La Roche Inc. Client Name Self

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address
 As noted on the first page, this registration also covers:
F. Hoffmann-La Roche Ltd.

21. Client new principal place of business (if different from line 20)
 City Basel State/Zip (or Country) Switzerland

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that no longer pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

| Name | Address | Principal Place of Business (city and state or country) |
|------|---------|---|
| | | |

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

| Name | Address | Principal place of business (city and state or country) | Amount of contribution for lobbying activities | Ownership percent client |
|--------------------------------|---------|---|--|--------------------------|
| Previously filed on Form LO-IU | | | \$10,000 | |

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

Signature *Michael Eging* Date 8/12/03
 Printed Name and Title Michael Eging, Exec. Dir., Federal Gov'n Affairs & Public Policy

